The treatment was reported to be effective in the shortterm. Brentuximab vedotin inn, trade name adcetris is an antibodydrug conjugate medication used to treat relapsed or refractory hodgkin lymphoma hl and systemic anaplastic large cell lymphoma alcl. Brentuximab vedotin desensitization in a patient with refractory. This cost assumes that partially used vials will be discarded and uses the regimen and mean duration of therapy 9. Brentuximab vedotin is an immunotherapy and chemotherapy combined into one medicine used to treat anaplastic large cell lymphoma and hodgkin lymphoma with a promising outlook in treatment of other subtypes of lymphoma. Retreatment with brentuximab vedotin monotherapy was investigated in patients with cd30positive hodgkin lymphoma hl or systemic anaplastic large cell lymphoma alcl who relapsed after achieving complete or partial remission cr or pr with initial brentuximab vedotin therapy in a previous study clinicaltrials. Adcetris brentuximab vedotin is indicated for treatment of patients with hodgkin lymphoma hl after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not asct candidates. Jc virus infection resulting in pml and death can occur in patients receiving adcetris 5. Study of brentuximab vedotin sgn35 in pediatric participants. Mmae is released via proteolytic cleavage of the dipeptide bond.
Dpi drug package insert epa environmental protection agency. Miralax prescribing information pdf highlights of prescribing information. Cd30directed antibodydrug conjugate therapeutic class. The phase iii aethera trial demonstrated the efficacy of brentuximab vedotin bv as consolidation therapy in patients with classical hodgkin. It is used for treating hodgkin lymphoma and certain nonhodgkin lymphomas, such as anaplastic largecell lymphoma, mycosis fungoides, and peripheral tcell lymphoma. Adcetris brentuximab vedotin package insert 12012 cited march 27, 20.
Medical calculators for the clinician, comprehensive guide to drug therapy, intravenous iv drug dilution, dosing calculators, nutrition and diet calculators. The printed package leaflet of the medicinal product must state the name and. Brentuximab adcetrishodgkins lymphoma chemoexperts. Adcetris is to be used in patients who have received two prior chemotherapy treatments and. Is brentuximab vedotin effective in hodgkin lymphoma. Adcetris, innbrentuximab vedotin european medicines agency. Highlights of prescribing information these highlights do not include all the information needed to use rituxan safely and effectively. Package label of brentuximab vedotin is ndc 5114405001. Hold dose of brentuximab for grade 3 or 4 neutropenia until resolution to baseline or grade 2 or lower. Cunningham jc virus infection in patients treated with brentuximab vedotin. Brentuximab vedotin with chemotherapy for stage iii or iv. The drug being tested in this study is called brentuximab vedotin. For more information, go to edit pdf content in word. Progressive multifocal leukoencephalopathy associated with.
Other risk factors include prior immunosuppressive therapies or underlying immunosuppressive disease. Following dilution, infuse the adcetris solution immediately. Brentuximab vedotin compared with other therapies in. Brentuximab vedotin caused embryofetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with hl and salcl. The appraisal committee has considered the evidence. Brentuximab vedotin is an anticd30 antibodydrug conjugate that has been approved for relapsed and refractory hodgkins lymphoma. How to use brentuximab vedotin solution, reconstituted recon soln this medication is given by injection into a vein over 30 minutes by a health care professional. Consider growth factor support for subsequent cycles for patients who developed grade 3 or 4 neutropenia. Food and drug administration fda is notifying the public that two additional cases of progressive multifocal leukoencephalopathy pml, a rare but serious brain infection. Retreatment with brentuximab vedotin in patients with cd30. Listing a study does not mean it has been evaluated by the u. Brentuximab vedotin works by targeting a particular marker on the cell which is referred to as cd30. Many prescription drugs and otc products can interact with miralax and affect here is some information on the product miralax that may be able to answer. It is made up of a monoclonal antibody, a type of protein designed to target and interfere with the growth of cancer cells, and a second drug.
Rituxan rituximab is indicated, in combination with fludarabine and cyclophosphamide fc, for the treatment of patients with previously untreated and previously treated cd20positive cll. Brentuximab vedotin is a cd30directed antibodydrug conjugate. Nivolumab combined with brentuximab vedotin for relapsed. Adcetris brentuximab vedotin is indicated for the treatment of. It selectively targets tumor cells expressing the cd30 antigen, a defining marker of hodgkin lymphoma and alcl a type of t cell nonhodgkin lymphoma. The current study examined the longterm effectiveness of brentuximab vedotin. Adcetris brentuximab vedotin for injection is supplied as a sterile, white to offwhite, preservativefree lyophilized cake or powder in singledose vials. Brentuximab vedotin in chinese participants with relapsed. Brentuximab vedotin is a monoclonal antibody and a chemotherapy drug. Keep using birth control for at least 6 months after your last dose of brentuximab vedotin. Brentuximab vedotin is used to treat classical hodgkin lymphoma. The cost of brentuximab per patient per year is estimated at 114,620 including 23% vat.
Brentuximab sticks to the cd30 protein and delivers a drug to the cell. Tucatinib is an orally bioavailable, small molecule tyrosine kinase inhibitor tki that is highly selective for her2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. Learn more about revlimid, a treatment option for multiple myeloma. Niosh list of antineoplastic and other hazardous drugs in. See full prescribing information for complete boxed warning. Hodgkin disease lymphoma, largecell, anaplastic, drug. Word will convert the pdf to editable text and you can then copy and paste that text into your office document. Brentuximab vedotin in patients with cd30positive nonlymphomatous malignancies the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The united states food and drug administration fda has accepted for filing a supplemental biologics license application bla based on data from the phase. Relapsed or refractory hodgkin lymphoma relapsed or refractory anaplastic largecell lymphoma, drug. Bonthapally v1, yang h, ayyagari r, tan rd, cai s, wu e, gautam a, chi a, huebner d. The recommended adcetris dosage is provided in table 1. Side effects of adcetris brentuximab vedotin, warnings, uses. Role of brentuximab vedotin in the treatment of relapsed or refractory hodgkin lymphoma.
Brentuximab vedotin recombinant for iv infusion special drug. These highlights do not include all the information needed to use. Brentuximab vedotin is given to shrink lymph nodes, alleviate symptoms of hodgkin lymphoma, and achieve disease remission. Brentuximab adcetris for hodgkin lymphoma patient advocacy group lfc. Brentuximab vedotin is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Adcetris is an antibodydrug conjugate composed of a cd30directed monoclonal. Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma.
If not used immediately, store the solution at 28c 3646f and use within 24 hours of reconstitution. Brentuximab vedotin for treating cd30positive hodgkins lymphoma the department of health has asked the national institute for health and care excellence nice to produce guidance on using brentuximab vedotin in the nhs in england. Brentuximab vedotin compared with other therapies in relapsedrefractory hodgkin lymphoma post autologous stem cell transplant. Adcetris brentuximab vedotin cost, side effects, package. Previously untreated stage iiiiv chl adult patients with previously untreated stage iiiiv classical hodgkin lymphoma chl in combination with doxorubicin, vinblastine, and dacarbazine. If youre looking to insert the contents of your pdf file into an office file, as opposed to simply inserting the pdf as an attachment, then your best bet is to open that pdf with word 20 or 2016.
Highlights of prescribing information the recommended. Niosh list of antineoplastic and other hazardous drugs in healthcare settings, 2016. Several cases have been reported in patients on the bcelldepleting anticd20 antibody, rituximab, and the adhesion molecule inhibitor, efalizumab, which binds the. Brentuximab definition of brentuximab by medical dictionary. Dailymed adcetris brentuximab vedotin injection, powder. Brentuximab vedotin for treating cd30 positive hodgkins. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using brentuximab vedotin. Antineoplastic pregnancy risk category d fda box warning john cunningham virus jcv infection resulting in progressive multifocal leukoencephalopathy pml and death has been reported in patients treated with brentuximab vedotin. In some cases, health care professionals may use the trade name, adcetris, when referring to the generic drug name, brentuximab vedotin. Brentuximab vedotin can harm an unborn baby or cause birth defects if the mother or father is using this medicine. Adcetris is indicated for the treatment of adult patients with relapsed or. Pml should be considered in any patient treated with brentuximab vedotin who presents with new onset of signs and symptoms of central nervous system abnormalities. Brentuximab vedotin side effects, dosage, interactions. Highlights of prescribing information these highlights do not include all the information needed to use adcetris safely and effectively.
Adcetris brentuximab vedotin is an antibody conjugated drug a combination of three components indicated for treatment of patients with hodgkin lymphoma hodgkins disease and for the treatment of patients with systemic anaplastic large cell lymphoma salcl. Erbitux can cause serious and fatal infusion reactions. Adcetris is approved in more than 45 countries, including brazil, japan, the united states and countries in the european union. Brentuximab targets a protein called cd30 that is found on hodgkin lymphoma and anaplastic large cell lymphoma cells. Brentuximab vedotin is an anticd30 antibody conjugated with the tubulin inhibitor mmae. A dilution of brentuximab was compounded by adding.
Safety analysis of brentuximab vedotin from the phase iii aethera. If remission is achieved, some patients may receive a bone marrow transplant with the goal of cure. Brentuximab vedotin solution, reconstituted recon soln. Full text brentuximab vedotin for treatment of relapsed. By connor th, mackenzie ba, debord dg, trout db, ocallaghan jp. Globalrph medical calculators, clinicians guide to drug. Prior authorization criteria adcetris brentuximab vedotin note. We conducted an openlabel, multicenter, randomized.
357 830 647 1025 488 565 93 629 1207 535 1026 764 294 1345 1346 81 1455 1473 530 349 184 1243 768 404 969 1447 1443 46 1123 584 479 332 145